Maraviroc + Exercise for Stroke Recovery
(CAMAROS Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing whether the drug Maraviroc, combined with exercise, can help stroke patients recover better. It targets patients shortly after their stroke because recovery often slows down after a few months. Maraviroc might help the brain and nerves heal more effectively when paired with exercise.
Will I have to stop taking my current medications?
You may need to stop taking certain medications to participate in this trial. Specifically, if you are currently taking anticonvulsants like Carbamazepine, Phenobarbital, or Phenytoin, or certain antifungal and antibacterial medications like Ketoconazole or Clarithromycin, you will need to stop. Also, if you are taking St. John's Wort or Paxlovid, you will need to discontinue those as well.
What data supports the effectiveness of the treatment Maraviroc + Exercise for Stroke Recovery?
Exercise and physical therapy have been shown to be beneficial for stroke recovery, as they can improve motor function and overall rehabilitation. Additionally, the use of selective serotonin reuptake inhibitors (a type of antidepressant) has been associated with improved motor recovery, suggesting that pharmacological interventions can aid in stroke rehabilitation.12345
How is the drug Maraviroc combined with exercise unique for stroke recovery?
Research Team
Bruce Dobkin, MD
Principal Investigator
University of California, Los Angeles, California, USA
Sean Dukelow, MD PhD FRCPC
Principal Investigator
University of Calgary, Calgary, Alberta, Canada
Eligibility Criteria
Adults over 18 with hemiparesis from a recent stroke needing inpatient rehab can join. They must have some arm or leg movement, had an ischemic stroke in the brain's anterior part, and be within 6 weeks post-stroke. Participants need support for daily practice and transport. Exclusions include pre-stroke disability, dementia, certain chronic illnesses including hepatitis or cancer, pregnancy, HIV positivity, specific medication use (e.g., anticonvulsants), and severe kidney issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline physical and cognitive assessments, including the use of wrist and ankle activity sensors
Treatment
Participants receive either Maraviroc or placebo alongside an 8-week daily exercise program
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 6 months post-stroke
Treatment Details
Interventions
- Activity Sensor
- Exercise Program
- Maraviroc
- Motor Learning
- Placebo
Maraviroc is already approved in United States, European Union, Canada for the following indications:
- HIV-1 infection in combination with other antiretroviral agents
- HIV-1 infection in combination with other antiretroviral agents
- HIV-1 infection in combination with other antiretroviral agents
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor
Parkwood Hospital, London, Ontario
Collaborator
Riverview Health Centre Foundation
Collaborator
Memorial University of Newfoundland
Collaborator
Dalhousie University
Collaborator
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Collaborator
University Health Network, Toronto
Collaborator
University of California, Los Angeles
Collaborator
Sunnybrook Health Sciences Centre
Collaborator
University of British Columbia
Collaborator